Biology of Blood and Marrow Transplantation
Volume 15, Issue 11 , Pages 1422-1430 , November 2009

Improved Nonrelapse Mortality and Infection Rate with Lower Dose of Antithymocyte Globulin in Patients Undergoing Reduced-Intensity Conditioning Allogeneic Transplantation for Hematologic Malignancies

  • Mehdi Hamadani

      Affiliations

    • Division of Hematology/Oncology, Blood and Marrow Transplantation Section, and the Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio
    • Corresponding Author InformationCorrespondence and reprint requests: Mehdi Hamadani, MD, Division of Hematology and Oncology, and Comprehensive Cancer Center, The Ohio State University, M365 Starling Loving Hall, 320 West 10th Avenue, Columbus, OH 43210.
    • ,
  • William Blum

      Affiliations

    • Division of Hematology/Oncology, Blood and Marrow Transplantation Section, and the Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio
    • ,
  • Gary Phillips

      Affiliations

    • The Ohio State University, Center for Biostatistics, Columbus, Ohio
    • ,
  • Patrick Elder

      Affiliations

    • Division of Hematology/Oncology, Blood and Marrow Transplantation Section, and the Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio
    • ,
  • Leslie Andritsos

      Affiliations

    • Division of Hematology/Oncology, Blood and Marrow Transplantation Section, and the Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio
    • ,
  • Craig Hofmeister

      Affiliations

    • Division of Hematology/Oncology, Blood and Marrow Transplantation Section, and the Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio
    • ,
  • Lynn O'Donnell

      Affiliations

    • Division of Hematology/Oncology, Blood and Marrow Transplantation Section, and the Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio
    • ,
  • Rebecca Klisovic

      Affiliations

    • Division of Hematology/Oncology, Blood and Marrow Transplantation Section, and the Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio
    • ,
  • Sam Penza

      Affiliations

    • Division of Hematology/Oncology, Blood and Marrow Transplantation Section, and the Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio
    • ,
  • Ramiro Garzon

      Affiliations

    • Division of Hematology/Oncology, Blood and Marrow Transplantation Section, and the Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio
    • ,
  • David Krugh

      Affiliations

    • Division of Hematology/Oncology, Blood and Marrow Transplantation Section, and the Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio
    • ,
  • Thomas Lin

      Affiliations

    • Division of Hematology/Oncology, Blood and Marrow Transplantation Section, and the Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio
    • ,
  • Thomas Bechtel

      Affiliations

    • Division of Hematology/Oncology, Blood and Marrow Transplantation Section, and the Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio
    • ,
  • Don M. Benson

      Affiliations

    • Division of Hematology/Oncology, Blood and Marrow Transplantation Section, and the Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio
    • ,
  • John C. Byrd

      Affiliations

    • Division of Hematology/Oncology, Blood and Marrow Transplantation Section, and the Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio
    • ,
  • Guido Marcucci

      Affiliations

    • Division of Hematology/Oncology, Blood and Marrow Transplantation Section, and the Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio
    • ,
  • Steven M. Devine

      Affiliations

    • Division of Hematology/Oncology, Blood and Marrow Transplantation Section, and the Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio

Received 13 June 2009 ,Accepted 7 July 2009.

  • Image Result

    Cumulative incidence of GVHD according to the ATG dosage group. (A) cumulative incidence of grade II-IV aGVHD. (B) Cumulative incidence of grade III-IV aGVHD. (C) Cumulative incidence of cGVHD. (D) Cu

    Cumulative incidence of GVHD according to the ATG dosage group. (A) cumulative incidence of grade II-IV aGVHD. (B) Cumulative incidence of grade III-IV aGVHD. (C) Cumulative incidence of cGVHD. (D) Cumulative incidence of extensive cGVHD. Solid curves represent patients receiving ATG at 6.0 mg/kg, whereas the dashed curves represent patients getting the 7.5 mg/kg ATG dose.

  • Image Result
    (A) Cumulative incidence of NRM according to the ATG dosage group. (B) Cumulative incidence of disease relapse according to the ATG dosage group. Solid curves represent patients receiving ATG at 6.0 m

    (A) Cumulative incidence of NRM according to the ATG dosage group. (B) Cumulative incidence of disease relapse according to the ATG dosage group. Solid curves represent patients receiving ATG at 6.0 mg/kg, whereas the dashed curves represent patients getting the 7.5 mg/kg ATG dose.

  • Image Result
    OS and PFS according to ATG dosage group. (A) Kaplan-Meier estimates of OS following allogeneic transplantation, (B) Kaplan-Meier estimates of PFS following allogeneic transplantation. Solid curves re

    OS and PFS according to ATG dosage group. (A) Kaplan-Meier estimates of OS following allogeneic transplantation, (B) Kaplan-Meier estimates of PFS following allogeneic transplantation. Solid curves represent patients receiving ATG at 6.0 mg/kg, whereas the dashed curves represent patients getting the 7.5 mg/kg ATG dose.

 Financial disclosure: See Acknowledgments on page 1429.

PII: S1083-8791(09)00325-5

doi: 10.1016/j.bbmt.2009.07.006

Biology of Blood and Marrow Transplantation
Volume 15, Issue 11 , Pages 1422-1430 , November 2009

Article Tools

* Image Usage & Resolution